Abstract:2503 Background: There is controversy around the applicability of TMB across cancer types and reliability between assays from different manufacturers. The KEYNOTE 158 trial supported FDA approval of the Foundation Medicine test (FoundationOne CDx) at TMB ≥ 10 mut/Mb as a solid tumor companion diagnostic (CDx) for single-agent pembrolizumab in 2 nd + line. Using a large real-world dataset with validated rwOS endpoint data, we evaluated the clinical validity of the TMB measurement by the FDA approved test in over 8,000 patients across 24 cancer types who received single agent ICI. Methods: Following a prespecified analysis plan, this study used the nationwide (US-based) de-identified Flatiron Health-Foundation Medicine clinico-genomic database (FH-FMI CGDB), with data originating from approximately 280 US cancer clinics (~800 sites of care). The overall cohort included patients from 24 cancer types of interest with adv/metastatic disease treated with single-agent anti-PD(L)1 therapy in the FH network between 1/1/2011 - 9/30/2022. This study used the TMB algorithm from the FDA-approved test supporting solid tumor CDx and composite mortality variable validated against the national death index. Relative hazards of death by TMB interval were assessed using Cox PH models adjusted for ECOG PS, prior treatment, sex, age, opioid rx pre-therapy, genetic ancestry, and socioeconomic assessment. Multi-solid tumor cohort Cox models were additionally adjusted for MSI status, with baseline hazards stratified by cancer type. Results: 8,440 patients from 24 cancer types met inclusion criteria for the overall cohort. Adjusting for aforementioned factors, the hazards of death {HR, (95% CI)} across the entire cohort, relative to TMB < 5, was 0.95 (0.89 – 1.02) for TMB 5-10, 0.79 (0.73 – 0.85) for TMB 10-20, and 0.52 (0.47 – 0.58) for TMB 20+. Adjusted Cox models comparing TMB ≥ 10 vs. TMB < 10 were pre-specified for cancer types with at least 15 death events in each group: breast 0.51 (0.35 - 0.76), colorectal 0.37 (0.27 - 0.49), cancers of unknown primary 0.52 (0.30 - 0.90), endometrial 0.38 (0.26 - 0.55), gastric 0.46 (0.34 - 0.62), head & neck 0.49 (0.33 - 0.73), melanoma 0.55 (0.43 - 0.71), non-small cell lung 0.76 (0.71 - 0.83), small cell lung 0.69 (0.44 - 1.09), and urothelial 0.63 (0.53 – 0.75). Additional individual tumor types, stratification by MSI status, and time to next treatment associations to be presented at conference. Conclusions: Across a heterogeneous cohort, and within individual cancer types with sufficient power, elevated TMB using the TMB measurement based on the FDA-approved test associated with more favorable rwOS on ICI than for similar patients with lower TMB levels. Completed and ongoing randomized controlled trials are encouraged to report out subgroup analyses comparing ICI vs. comparator arm by TMB level.

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab{plus minus}Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy

Blood Tumor Mutation Burden Can Predict the Clinical Response to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI).

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

Tumor Mutational Burden Identifies Chemorefractory Gastric Cancer with Overall Survival Advantage after Receiving Toripalimab, a PD-1 Antibody.

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782

The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis

Association of alterations in DNA damage repair and Notch pathways with high tumor mutational burden in patients with cervical cancer.

Baseline Lesion Number As an Efficacy Predictive and Independent Prognostic Factor and Its Joint Utility with TMB for PD-1 Inhibitor Treatment in Advanced Gastric Cancer

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis

Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic